[{"id":"659160cb-410e-4379-bdd3-f303bb40e1fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05094336","created_at":"2021-10-26T20:53:08.844Z","updated_at":"2025-02-25T13:54:05.475Z","phase":"Phase 1/2","brief_title":"A Study of AMG 193 in Subjects With Advanced MTAP-[] Solid Tumors","source_id_and_acronym":"NCT05094336","lead_sponsor":"Amgen","biomarkers":" CDKN2A • MTAP","pipe":"","alterations":" ","tags":["CDKN2A • MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • AMG 193"],"overall_status":"Recruiting","enrollment":" Enrollment 649","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 08/02/2026","primary_completion_date":" 08/02/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-20"},{"id":"6e960e10-a292-4eb9-ac61-0062dbf094ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05975073","created_at":"2023-08-03T15:09:55.318Z","updated_at":"2024-07-02T16:34:37.673Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors","source_id_and_acronym":"NCT05975073","lead_sponsor":"Amgen","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDE397 • AMG 193"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 12/03/2026","study_completion_date":" 12/03/2026","last_update_posted":"2024-06-06"}]